H1N1 백신 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측 : 투여 경로별, 브랜드 유형별, 유통 채널별, 지역별, 경쟁별(2020-2030년)
H1N1 Vaccines Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Route of Administration, By Type of Brand, By Distribution Channel, By Region & Competition, 2020-2030F
상품코드:1691804
리서치사:TechSci Research
발행일:2025년 03월
페이지 정보:영문 186 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
H1N1 백신 세계 시장 규모는 2024년 99억 1,000만 달러로 2030년까지 예측 기간 동안 4.23%의 CAGR을 기록하며 괄목할 만한 성장을 보일 것으로 예상됩니다.
H1N1 백신 세계 시장은 주로 H1N1 인플루엔자 바이러스의 예방 및 확산 억제에 초점을 맞춘 헬스케어 산업의 중요한 구성요소로, 일반적으로 돼지 인플루엔자로 알려진 H1N1 인플루엔자 바이러스의 예방 및 확산 억제에 초점을 맞추고 있습니다. H1N1 백신 세계 시장은 독감 유행의 증가와 백신 접종 프로그램에 대한 인식의 증가 등 여러 요인에 의해 주도되고 있습니다. 전 세계 정부와 의료 기관은 계절성 독감 및 유행성 독감을 예방하기 위해 예방접종에 투자하고 있으며, 이는 H1N1 백신에 대한 수요를 촉진하고 있습니다. 신종 인플루엔자 감염으로 인해 심각한 합병증을 유발하기 쉬운 노인 인구의 증가는 시장 성장을 더욱 촉진하고 있습니다. 예를 들어, 2023년 10월에 발표된 CDC의 추정에 따르면, 전 세계적으로 약 10억 건의 계절성 독감 사례가 발생했으며, 그 중 약 300만-500만 건이 중증으로 분류됩니다. 감시 강화, 유통, 공급 및 투여 모니터링에 중점을 둔 국가 및 세계 차원에서 백신 접종에 대한 정부의 강력한 지원은 시장 성장을 촉진하는 중요한 요소입니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
99억 1,000만 달러
시장 규모 : 2030년
126억 달러
CAGR : 2025-2030년
4.23%
급성장 부문
온라인 약국
최대 시장
북미
재조합 백신과 보조 백신을 포함한 백신 개발의 발전으로 백신 효능이 향상되고 보급이 촉진되고 있습니다. 신종 H1N1 바이러스 균주의 출현으로 백신의 지속적인 업데이트가 필요하게 되어 시장 확대를 촉진하고 있습니다. 활발한 연구개발 활동, WHO 및 CDC 등 세계보건기구의 자금 지원, 제약기업 간의 전략적 제휴는 백신의 신속한 개발 및 유통에 기여하고 있으며, COVID-19의 대유행으로 호흡기 감염에 대한 국민들의 인식이 높아져 백신 인프라가 강화되었습니다. 정부의 고위험군에 대한 독감 백신 접종 의무화 확대와 유리한 상환 정책은 시장 성장을 더욱 촉진하고 있습니다. 세포 기반 및 mRNA 플랫폼을 포함한 백신 제조의 기술 발전은 효율성과 확장성을 향상시키고 있습니다. 따라서 보다 광범위한 독감 예방 효과를 제공하는 혼합 백신에 대한 수요 증가는 향후 몇 년 동안 기술 혁신과 시장 확대의 원동력이 될 것으로 예상됩니다.
주요 시장 촉진요인
팬데믹 대비 및 인식 제고
주요 시장 과제
바이러스의 변이와 진화
주요 시장 동향
범용 독감 백신
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 세계의 H1N1 백신 시장 전망
시장 규모 및 예측
금액별
시장 점유율과 예측
투여 경로별(피내 백신, 근육내 백신, 비강내 백신)
브랜드 유형별(Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip)
유통 채널별(병원 약국, 소매 약국, 온라인 약국)
지역별
기업별(2024)
제품 시장 맵
투여 경로별
브랜드별
유통 채널별
지역별
제6장 북미의 H1N1 백신 시장 전망
시장 규모 및 예측
시장 점유율과 예측
북미 : 국가별 분석
미국
캐나다
멕시코
제7장 유럽의 H1N1 백신 시장 전망
시장 규모 및 예측
시장 점유율과 예측
유럽 : 국가별 분석
독일
영국
프랑스
이탈리아
스페인
제8장 아시아태평양의 H1N1 백신 시장 전망
시장 규모 및 예측
시장 점유율과 예측
아시아태평양 : 국가별 분석
중국
일본
인도
호주
한국
제9장 남미의 H1N1 백신 시장 전망
시장 규모 및 예측
시장 점유율과 예측
남미 : 국가별 분석
브라질
아르헨티나
콜롬비아
제10장 중동 및 아프리카의 H1N1 백신 시장 전망
시장 규모 및 예측
시장 점유율과 예측
중동 및 아프리카 : 국가별 분석
남아프리카공화국
사우디아라비아
아랍에미리트
쿠웨이트
제11장 시장 역학
성장 촉진요인
과제
제12장 시장 동향과 발전
최근 동향
인수합병
제품 출시
제13장 Porter's Five Forces 분석
업계내 경쟁
신규 참여의 가능성
공급업체의 능력
고객의 능력
대체품의 위협
제14장 경쟁 구도
AstraZeneca PLC
Sanofi Pasteur MSD AG
GSK PLC
Abbott Laboratories Inc
CSL Ltd
Pfizer Inc
CPL Biologicals Pvt Ltd
Mitsubishi Tanabe Pharma Corp
Sinovac Biotech Co Ltd
Zydus Lifesciences Ltd
제15장 전략적 제안
제16장 조사 회사 소개 및 면책사항
ksm
영문 목차
영문목차
Global H1N1 Vaccines Market was valued at USD 9.91 billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 4.23% through 2030. The global H1N1 vaccines market is a crucial component of the healthcare industry, primarily focused on preventing and controlling the spread of the H1N1 influenza virus, commonly known as swine flu. The global H1N1 vaccines market is driven by multiple factors, primarily the rising prevalence of influenza outbreaks and the increasing awareness of vaccination programs. Governments and healthcare organizations worldwide are investing in immunization initiatives to prevent seasonal and pandemic influenza, fueling demand for H1N1 vaccines. The growing elderly population, which is more susceptible to severe complications from H1N1 infections, further boosts market growth. For instance, according to CDC estimates published in October 2023, nearly one billion cases of seasonal influenza occur worldwide, with approximately 3-5 million classified as severe. The increased surveillance efforts and strong government support for vaccination at both national and global levels-focusing on monitoring distribution, supply, and administration-are key factors driving market growth.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 9.91 Billion
Market Size 2030
USD 12.60 Billion
CAGR 2025-2030
4.23%
Fastest Growing Segment
Online Pharmacies
Largest Market
North America
Advancements in vaccine development, including recombinant and adjuvanted vaccines, enhance efficacy and drive adoption. The emergence of new H1N1 virus strains necessitates continuous vaccine updates, supporting market expansion. Increasing R&D activities, funding from global health organizations such as the WHO and CDC, and strategic collaborations among pharmaceutical companies contribute to the rapid development and distribution of vaccines. The COVID-19 pandemic has heightened public awareness of respiratory infections, strengthening the overall vaccine infrastructure. Expanding government mandates for influenza vaccination in high-risk groups, coupled with favorable reimbursement policies, further stimulate market growth. Technological advancements in vaccine production, including cell-based and mRNA platforms, offer improved efficiency and scalability. Therefore, the rising demand for combination vaccines that provide broader influenza protection is expected to drive innovation and market expansion in the coming years.
Key Market Drivers
Pandemic Preparedness and Awareness
Pandemic preparedness and awareness play a crucial role in driving the growth of the global H1N1 vaccines market. Governments, health organizations, and pharmaceutical companies have intensified efforts to strengthen pandemic response strategies, ensuring rapid vaccine development, stockpiling, and distribution. The World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) continue to promote global surveillance programs, early detection systems, and public awareness campaigns, increasing the demand for H1N1 vaccines. The COVID-19 pandemic has further underscored the importance of robust vaccination programs, leading to improved healthcare infrastructure and vaccine supply chains. Growing public awareness about the risks of influenza pandemics has encouraged higher vaccination rates, particularly among vulnerable populations such as the elderly, pregnant women, and immunocompromised individuals. Governments worldwide are implementing mandatory vaccination policies for healthcare workers and high-risk groups, boosting market expansion. The pandemic preparedness initiatives have led to significant investments in vaccine research, resulting in the development of more effective and rapidly deployable H1N1 vaccines, including cell-based and mRNA-based formulations. Increased collaboration between public and private sectors has accelerated vaccine accessibility, further driving market growth. As global preparedness measures continue to evolve, the demand for H1N1 vaccines is expected to rise, ensuring better pandemic resilience. According to the World Health Organization (WHO), seasonal influenza causes approximately 3 to 5 million cases of severe illness and between 290,000 to 650,000 respiratory-related deaths annually. In industrialized countries, the majority of influenza-related deaths occur in individuals over 65 years old. Seasonal influenza can lead to a wide range of health outcomes, from mild illness to severe complications and even death.
Key Market Challenges
Virus Mutations and Evolution
Perhaps the most significant challenge in the H1N1 vaccines market is the constant evolution of the virus. H1N1 influenza strains mutate regularly, making it necessary to update vaccine formulations to match the currently circulating strains. This requires ongoing research, surveillance, and timely adjustments in vaccine production, driving the need for advanced manufacturing technologies and robust global monitoring systems. Governments and health organizations, such as the WHO and CDC, play a crucial role in identifying dominant strains and recommending vaccine updates, ensuring continued market demand. The pharmaceutical companies invest heavily in innovative vaccine platforms, such as mRNA and cell-based technologies, to enable faster production and adaptability to viral mutations. The unpredictable nature of influenza outbreaks necessitates strategic vaccine stockpiling and rapid distribution systems, further fueling market growth. As global health preparedness efforts intensify, the demand for adaptable and effective H1N1 vaccines continues to rise, supporting the expansion of the market.
Key Market Trends
Universal Influenza Vaccines
One of the most promising trends driving the growth of the global H1N1 vaccines market is the development of universal influenza vaccines. Unlike traditional seasonal flu vaccines, which require frequent updates to match circulating strains, universal vaccines aim to provide long-lasting immunity against multiple influenza subtypes, including H1N1. These vaccines target conserved regions of the virus, such as hemagglutinin stalk domains and internal viral proteins, which undergo fewer mutations compared to surface antigens. By inducing broader immune responses, universal vaccines could significantly reduce the burden of annual vaccinations and enhance pandemic preparedness. Pharmaceutical companies and research institutions are actively investing in advanced vaccine platforms, including mRNA, viral vector, and nanoparticle-based approaches, to accelerate universal vaccine development. The growing support from governments and global health organizations is further driving clinical trials and regulatory approvals. A successful universal influenza vaccine could streamline vaccine manufacturing, reducing production costs and distribution challenges. This breakthrough would be particularly beneficial for low- and middle-income countries with limited healthcare resources, improving global access to influenza prevention. As research progresses and technological advancements continue, universal influenza vaccines have the potential to transform the H1N1 vaccines market, offering a more efficient and sustainable approach to combating influenza outbreaks worldwide.
Key Market Players
AstraZeneca PLC
Sanofi Pasteur MSD AG
GSK PLC
Abbott Laboratories Inc
CSL Ltd
Pfizer Inc
CPL Biologicals Pvt Ltd
Mitsubishi Tanabe Pharma Corp
Sinovac Biotech Co Ltd
Zydus Lifesciences Ltd
Report Scope:
In this report, the Global H1N1 Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
H1N1 Vaccines Market, By Route of Administration:
Intradermal Vaccines
Intramuscular Vaccines
Intranasal Vaccines
H1N1 Vaccines Market, By Type of Brand:
Agripal
Fiuarix
Influgen
Influvac
Nasovac
Vaxigrip
H1N1 Vaccines Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
H1N1 Vaccines Market, By Region:
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Asia-Pacific
China
Japan
India
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global H1N1 Vaccines Market.
Available Customizations:
Global H1N1 Vaccines market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global H1N1 Vaccines Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Route of Administration (Intradermal Vaccines, Intramuscular Vaccines, Intranasal Vaccines)
5.2.2. By Type of Brand (Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip)
5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
5.2.4. By Region
5.2.5. By Company (2024)
5.3. Product Market Map
5.3.1. By Route of Administration
5.3.2. By Type of Brand
5.3.3. By Distribution Channel
5.3.4. By Region
6. North America H1N1 Vaccines Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Route of Administration (Intradermal Vaccines, Intramuscular Vaccines, Intranasal Vaccines)
6.2.2. By Type of Brand (Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip)
6.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States H1N1 Vaccines Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Route of Administration
6.3.1.2.2. By Type of Brand
6.3.1.2.3. By Distribution Channel
6.3.2. Canada H1N1 Vaccines Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Route of Administration
6.3.2.2.2. By Type of Brand
6.3.2.2.3. By Distribution Channel
6.3.3. Mexico H1N1 Vaccines Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Route of Administration
6.3.3.2.2. By Type of Brand
6.3.3.2.3. By Distribution Channel
7. Europe H1N1 Vaccines Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Route of Administration (Intradermal Vaccines, Intramuscular Vaccines, Intranasal Vaccines)
7.2.2. By Type of Brand (Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip)
7.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany H1N1 Vaccines Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Route of Administration
7.3.1.2.2. By Type of Brand
7.3.1.2.3. By Distribution Channel
7.3.2. United Kingdom H1N1 Vaccines Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Route of Administration
7.3.2.2.2. By Type of Brand
7.3.2.2.3. By Distribution Channel
7.3.3. France H1N1 Vaccines Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Route of Administration
7.3.3.2.2. By Type of Brand
7.3.3.2.3. By Distribution Channel
7.3.4. Italy H1N1 Vaccines Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Route of Administration
7.3.4.2.2. By Type of Brand
7.3.4.2.3. By Distribution Channel
7.3.5. Spain H1N1 Vaccines Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Route of Administration
7.3.5.2.2. By Type of Brand
7.3.5.2.3. By Distribution Channel
8. Asia-Pacific H1N1 Vaccines Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Route of Administration (Intradermal Vaccines, Intramuscular Vaccines, Intranasal Vaccines)
8.2.2. By Type of Brand (Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip)
8.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China H1N1 Vaccines Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Route of Administration
8.3.1.2.2. By Type of Brand
8.3.1.2.3. By Distribution Channel
8.3.2. Japan H1N1 Vaccines Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Route of Administration
8.3.2.2.2. By Type of Brand
8.3.2.2.3. By Distribution Channel
8.3.3. India H1N1 Vaccines Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Route of Administration
8.3.3.2.2. By Type of Brand
8.3.3.2.3. By Distribution Channel
8.3.4. Australia H1N1 Vaccines Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Route of Administration
8.3.4.2.2. By Type of Brand
8.3.4.2.3. By Distribution Channel
8.3.5. South Korea H1N1 Vaccines Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Route of Administration
8.3.5.2.2. By Type of Brand
8.3.5.2.3. By Distribution Channel
9. South America H1N1 Vaccines Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Route of Administration (Intradermal Vaccines, Intramuscular Vaccines, Intranasal Vaccines)
9.2.2. By Type of Brand (Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip)
9.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil H1N1 Vaccines Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Route of Administration
9.3.1.2.2. By Type of Brand
9.3.1.2.3. By Distribution Channel
9.3.2. Argentina H1N1 Vaccines Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Route of Administration
9.3.2.2.2. By Type of Brand
9.3.2.2.3. By Distribution Channel
9.3.3. Colombia H1N1 Vaccines Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Route of Administration
9.3.3.2.2. By Type of Brand
9.3.3.2.3. By Distribution Channel
10. Middle East and Africa H1N1 Vaccines Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Route of Administration (Intradermal Vaccines, Intramuscular Vaccines, Intranasal Vaccines)
10.2.2. By Type of Brand (Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip)
10.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
